Back HIV/Hepatitis Coinfection

Coinfection

HIV/HCV Coinfected Have Stronger CD8 T-cell Response to HCV

HIV positive people coinfected with hepatitis C virus (HCV) demonstrated stronger CD8 T-cell responses against HCV, which may contribute to accelerated liver disease progression.

Read more:

Treatment Interruption Spurs Fibrosis in HIV/HCV Coinfected People

Stopping antiretroviral therapy led to liver fibrosis progression in HIV/HCV coinfected people, an effect that was not fully attributable to increased HIV viral load or reduced CD4 cell count.

Read more:

CROI 2011: Acute Hepatitis C Treatment for HIV/HCV Coinfected People

About 65% of coinfected patients with HCV genotypes 1 or 4, and 81% with genotypes 2 or 3, achieved sustained response to interferon-based therapy started during acute infection, researchers reported at CROI 2011.

Read more:

EASL 2011: HIV/HCV Coinfection among HIV Positive Gay Men

Researchers at EASL presented further data on outbreaks of sexually transmitted HCV among HIV positive men who have sex with men. Sustained response rates are high when interferon-based therapy is started during acute infection, but re-infection after treatment is common in this population. alt

Read more:

Tenofovir Remains Effective against Hepatitis B Virus after 5 Years in HIV/HBV Coinfected Patients

Tenofovir (Viread, also in the Truvada and Atripla combination pills) continues to potently suppress both hepatitis B virus (HBV) and HIV in coinfected patients for at least 5 years, according to a study published in the December 2010 issue of Gastroenterology. The findings support current guidelines recommending that HIV/HBV coinfected people should receive an antiretroviral therapy (ART) regimen that includes drugs with dual action against both viruses.

Read more:

EASL 2011: Kidney Function in HIV/HBV Coinfected People on Tenofovir

Impaired kidney function among people with HIV, HBV, and HIV/HBV coinfection taking tenofovir mainly occurred in those with pre-existing risk factors, researchers reported at EASL 2011. alt

Read more:

ICAAC 2011: HCV Drug Telaprevir Shows No Problematic Interactions with Raltegravir

The new hepatitis C virus (HCV) protease inhibitor telaprevir (Incivek) does not appear to have clinically relevant drug-drug interactions with the HIV integrase inhibitor raltegravir (Isentress), according to a study presented at the 51st Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC 2011) last month in Chicago.alt

Read more:

EASL 2011: Liver Disease Progression in HIV/HCV Coinfected People

Liver stiffness measured by FibroScan is a good predictor of liver cancer, end-stage liver disease or death among people with HIV/HCV coinfection, researchers reported as EASL 2011.

Read more:

Coinfected People May Control HIV but not HBV on a Tenofovir Regimen

More then one-third of people coinfected with HIV and hepatitis B virus (HBV) did not achieve or maintain HBV suppression after 1 year of taking tenofovir (Viread), even though they had undetectable HIV viral load indicating good adherence, according to study findings presented at the recent American Association for the Study of Liver Diseases "Liver Meeting" (AASLD 2010) in Boston.

Read more: